A new study led by researchers at the Ineos Oxford Institute for antimicrobial research (IOI) has found that antimicrobial resistant bacteria is spreading rapidly among children being treated for severe malnutrition in a hospital facility in Niger. The findings have been published today (1 August) in Nature Communications
Globally 45 million children under the age of five are estimated to be severely malnourished. These children are also at a higher risk of developing life-threatening infections such as tuberculosis or sepsis due to their weakened immune systems.
Working with Médecins Sans Frontières (Doctors Without Borders), researchers analysed over 3,000 rectal swabs from 1,371 children under the age of five being treated for severe malnutrition between 2016 and 2017.
Their findings showed that:
Antibiotics are life-saving medicines that are becoming ineffective due to antimicrobial resistance (AMR)- a process in which bacteria, fungi and parasites have developed the ability to resist the action of medicines.
If antibiotic-resistant bacteria remain in the gut, these children could be at risk of developing infections such as pneumonia, sepsis, diarrhoea and urinary tract infections in the future that do not respond to antibiotic treatment.
Dr Kirsty Sands , Scientific Lead, Ineos Oxford Institute for antimicrobial research and lead author said: “These are some of the most vulnerable children in the world, and we’re seeing them pick up bacteria that don’t respond to life-saving antibiotics.
“While our study was focused in one treatment facility in Niger, this situation is likely mirrored in many more hospitals around the world. As AMR continues to increase globally, concurrent humanitarian crises such as wars and climate change are exacerbating malnutrition, leading to overcrowded treatment centres.”
Dr Céline Langendorf, Lab Coordinator, Epicentre, MSF and co-author of the study, said : “Our latest findings highlight the urgent need to prioritise infection prevention and control measures in hospitals to protect the most vulnerable patients. In crowded hospitals with limited resources, these bacteria can spread easily from child to child. Without urgent action, more children could die from infections that used to be easy to treat.”
Professor Owen B. Spiller, Head of Medical Microbiology at Cardiff University and co-author of the study , said: “This research provides stark evidence that humanitarian crises amplify the silent pandemic of antimicrobial resistance. Without coordinated international action, combining antimicrobial stewardship, surveillance, and improved hygiene infrastructure, resistant bacteria will continue to spread unchecked. We urgently need global investment to safeguard antibiotics for children facing severe malnutrition in resource-limited settings.”
Researchers used genome sequencing to track the spread of these resistant bacteria. Most E. coli carrying bla NDM-5 were genetically very similar, suggesting likely transmission within the hospital setting. The resistance genes were carried on plasmids—mobile pieces of DNA that can jump between bacteria—making spread between species even more likely.
Notes to editor
For media enquiries and interview requests, contact Caroline Wood, University of Oxford: caroline.wood@admin.ox.ac.uk
The paper ‘Acquisition of Escherichia coli carrying extended-spectrum ß-lactamase and carbapenemase genes by hospitalised children with severe acute malnutrition in Niger’ will be published in Nature Communications at 5 AM ET / 10 AM BST Friday 1 August at https://www.nature.com/articles/s41467-025-61718-w To view a copy of the paper before this under embargo, contact Caroline Wood, University of Oxford: caroline.wood@admin.ox.ac.uk
About the Ineos Oxford Institute for antimicrobial research
The Ineos Oxford Institute for antimicrobial research (IOI) is a world-leading centre of research, training and education based at the University of Oxford. The IOI is developing solutions to fight antimicrobial resistance by developing new drugs for human use and designing alternative antibiotics to use in agriculture and animal feed exclusively.
About the University of Oxford
Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the ninth year running, and number 3 in the QS World Rankings 2024. At the heart of this success are the twin-pillars of our ground-breaking research and innovation and our distinctive educational offer.
Oxford is world-famous for research and teaching excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research alongside our personalised approach to teaching sparks imaginative and inventive insights and solutions.
Through its research commercialisation arm, Oxford University Innovation, Oxford is the highest university patent filer in the UK and is ranked first in the UK for university spinouts, having created more than 300 new companies since 1988. Over a third of these companies have been created in the past five years. The university is a catalyst for prosperity in Oxfordshire and the United Kingdom, contributing around £16.9 billion to the UK economy in 2021/22, and supports more than 90,400 full time jobs.
Nature Communications
Acquisition of Escherichia coli carrying extended-spectrum ß-lactamase and carbapenemase genes by hospitalised children with severe acute malnutrition in Niger
1-Aug-2025